Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma raises $108K in two convertible note financings in Feb 2025

Propanc Biopharma, Inc.

$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.
$43,000 convertible note (purchase price $40,000) issued Feb 10; 8% annual interest, maturity Oct 7, 2025.
First note convertible at 35% discount to lowest 10-day trading price; second note at $9/share (or $6 if stock <$8 for 5 days).
Proceeds used for general working capital; notes sold in unregistered offerings under Rule 506(b) and Section 4(a)(2).
Both notes contain events of default including failure to pay, breach of covenants, and conversion share issuance delays.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $65,000 at one-time interest charge of fifteen percent (15%) maturing November 30, 2025.

Instrument: convertible notes
Principal: $65,000
Rate: one-time interest charge of fifteen percent (15%)
Maturity: November 30, 2025
Event: incurrence

Exact text from the filing

the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $65,000

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $43,000 at eight percent (8%) per annum maturing October 7, 2025.

Instrument: convertible notes
Principal: $43,000
Rate: eight percent (8%) per annum
Maturity: October 7, 2025
Event: incurrence

Exact text from the filing

the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $43,000

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-006126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.